查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1284225

2028 年癌症生物標誌物市場預測——按癌症類型、產品類型、分析技術、應用、生物標誌物類型、服務和地區進行的全球分析

Cancer Biomarkers Market Forecasts to 2028 - Global Analysis By Cancer Type, Product, Profiling Technologies, Application, Biomarkers Type, Service and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 175+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，2022 年全球癌症生物標誌物市場規模將達到 147 億美元，預計到 2028 年將達到 409.2 億美元，預計將以 18.6% 的複合年增長率增長。

在腫瘤學中，生物標誌物是由腫瘤或某些身體反應分泌的物質，用於指示惡性腫瘤的存在。 使用多種基因組學和蛋白□□質組學技術，生物標誌物可以實現癌症的早期檢測和快速、非侵入性診斷。 生物標誌物的應用包括預後預測、個性化醫療、藥物研發和癌症診斷。

據美國國家癌症研究所估計，2018 年美國新診斷出 1,735,350 名癌症患者。 根據國際世界癌症研究基金會的數據，2018 年全球估計有 1800 萬人受到影響。 肺癌和乳腺癌是全球最常報告的癌症，佔 2018 年確診病例總數的 12.3%。

市場動態

驅動程序

癌症患病率上升

癌症生物標誌物廣泛用於個性化醫療、伴隨診斷和其他疾病診斷，包括疾病風險評估和藥物開發。 預計在預測期內推動癌症生物標誌物市場增長的主要因素之一是生物標誌物在疾病診斷中的使用越來越多。 全球癌症患病率上升正在增加對該疾病早期檢測的需求，這反過來又推動了市場的擴張。 隨著癌症生物標誌物在新興國家和發達國家變得更加普遍，預計對癌症診斷和治療的需求將會增加。

約束

治療費用高

危害患者獲得治療和癌症治療有效性的一個全球性問題是抗癌藥物成本的上升。 藥物的價格因國家而異。 在沒有全民醫療保健的國家，患者必須支付醫療費用。 低收入和中等收入國家的大多數患者負擔不起新的癌症治療費用。 年輕患者、新移民、有色人種和沒有私人醫療保險的人面臨的風險最大。 基於價值的癌症治療定價可以推動開發更好的藥物並減少不必要的支出。

機會

存在潛在管道候選者

製藥行業正在大力投資尋找可用於監測和識別癌症的新型生物標誌物。 一些候選人的開發週期即將結束。 預計這將顯著提高市場增長率。 例如，隆德大學醫院正在與南瑞典乳腺癌組織合作開展一項臨床試驗，比較阿托伐他汀的療效和安全性。 創建用於癌症早期診斷的新生物標誌物應該是癌症生物標誌物領域的優勢。 由於癌症生物標誌物相關商品和診斷試劑的擴張，預計市場將擴大。

威脅：

缺乏生物標誌物檢測報銷政策

儘管全球癌症患病率不斷上升，需要診斷檢測的患者數量不斷增加，但新興國家和發達國家缺乏生物標誌物檢測報銷政策，已成為限制全球生物標誌物需求的因素之一。 在新興國家，癌症診療費用高昂也是限制市場增長的關鍵問題。 因此，接受生物標誌物檢測的患者越來越少，越來越多的患者更喜歡其他更便宜的檢測方法。

COVID-19 的影響：

由於在此期間研發活動中斷，COVID-19 大流行對癌症生物標誌物市場產生了負面影響。 此外，SARS-CoV-2 感染還會產生難以解釋的生物標誌物數據。 例如，根據內分泌學會 2020 年 9 月提供的信息，由於對急性病毒感染的強烈免疫反應具有潛在的混雜效應，因此很難解釋對癌症的免疫反應指標。 此外，國家生物技術信息中心報告稱，由於 COVID-19 大流行，英國的常規癌症篩查已被推遲。

預計在預測期內乳腺癌細分市場最大

據估計，乳腺癌領域的增長利潤豐厚。 乳腺癌患病率的上升及其診斷意識的提高導致大量患者接受診斷測試。 影響乳腺癌領域發展的一個主要原因還包括越來越多的研究活動集中在用於乳腺癌檢測的新生物標誌物上。

預計診斷部門在預測期內的複合年增長率最高。

癌症檢測和治療的進步已將重點從治癒疾病的近期目標轉移到改善癌症倖存者（尤其是兒童癌症倖存者）的生活質量的長期目標。診斷領域有望增長在預測期內以最快的複合年增長率。 伴隨診斷測試在癌症治療中的普及有望推動市場增長。

市場份額最高的地區

由於癌症患者人數眾多，預計亞太地區在預測期內將佔據最大的市場份額。 提高公眾對癌症早期檢測必要性的認識是推動該地區市場增長的關鍵因素之一。 此外，該地區人口眾多也有助於市場增長。

複合年增長率最高的地區：

預計歐洲在預測期內的複合年增長率最高。 正在鑑定對癌症風險評估和癌症早期檢測很重要的生物標誌物。 生物標誌物，尤其是與遺傳因素相關的生物標誌物，提供了一種定量方法來確定一個人何時更有可能患上癌症。 該地區市場擴張的驅動力是在各種惡性腫瘤患病率上升的背景下，對癌症診斷的需求不斷增長。

主要發展：

2021 年 3 月，羅氏宣布 VENTANA ALK (D5F3) CDx 檢測獲得美國食品和藥物管理局批准作為伴隨診斷。 該試驗是唯一獲得 FDA 批准的 Lorbrena 伴隨診斷，使具有這種癌症生物標誌物的患者能夠被快速識別和更有效地治療。

2020 年 11 月，安捷倫科技公司宣布啟動“生物標誌物病理學家培訓計劃”，這是一項旨在幫助病理學家準確地對生物標誌物進行評分的全球性努力。做到了。 該計劃最初在歐洲和北美以及中國和亞洲使用數字平台提供。

2020年7月，Thermo Fisher Scientific宣布與Chugai Pharmaceutical Co., Ltd.簽訂伴隨診斷（CDx）協議，並已向厚生勞動省申請擴大使用Oncomin Dx日本目標測試 該協議的重點是在日本加速對 entrectinib 適應症的 NSCLC 患者進行當地生物標誌物測試。

這份報告提供了什麼

  • 區域和國家級細分市場的市場份額評估
  • 向新進入者提出戰略建議
  • 2020、2021、2022、2025 和 2028 年的綜合市場數據
  • 市場趨勢（驅動因素、制約因素、機會、威脅、挑戰、投資機會、建議）
  • 根據市場預測在關鍵業務領域提出戰略建議
  • 競爭格局映射關鍵共同趨勢。
  • 公司簡介，包括詳細的戰略、財務狀況和近期發展
  • 映射最新技術進步的供應鏈趨勢

免費定制優惠：

購買此報告的客戶將獲得以下免費定制選項之一：

  • 公司簡介
    • 其他市場參與者的綜合概況（最多 3 家公司）
    • 主要參與者的 SWOT 分析（最多 3 家公司）
  • 區域細分
    • 根據客戶的要求對主要國家/地區的市場估計/預測/複合年增長率（注意：基於可行性檢查）。
  • 競爭基準
    • 根據產品組合、區域影響力和戰略聯盟對主要參與者進行基準測試

內容

第 1 章執行摘要

第二章前言

  • 概覽
  • 利益相關者
  • 調查範圍
  • 調查方法
    • 數據挖掘
    • 數據分析
    • 數據驗證
    • 研究方法
  • 調查來源
    • 主要研究來源
    • 二級研究來源
    • 假設

第三章市場趨勢分析

  • 司機
  • 約束因素
  • 機會
  • 威脅
  • 產品分析
  • 技術分析
  • 應用分析
  • 新興市場
  • COVID-19 的影響

第 4 章波特五力分析

  • 供應商的議價能力
  • 買家的議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭公司之間的敵對關係

第 5 章全球癌症生物標誌物市場：按癌症類型分類

  • 黑色素瘤
  • 膀胱癌
  • 乳腺癌
  • 腎癌
  • 前列腺癌
  • 肺癌
  • 非霍奇金淋巴瘤
  • 結直腸癌
  • 甲狀腺癌
  • 白血病
  • 其他

第 6 章全球癌症生物標誌物市場：按產品分類

  • 軟件
  • 消耗品
  • 生長激素療法
  • 服務
  • 其他

第 7 章全球癌症生物標誌物市場：按分析技術

  • 免疫測定
  • 組學技術
  • 細胞遺傳學
  • 影像技術
  • 生物信息學
  • 其他

第 8 章全球癌症生物標誌物市場：按應用

  • 預後
  • 診斷
  • 風險評估
  • 研發
  • 醫院和專科診所
  • 製藥和生物技術公司
  • 其他用途

第 9 章全球癌症生物標誌物市場：按生物標誌物類型分類

  • 遺傳生物標誌物
  • 蛋白質生物標誌物
  • 安全
  • 藥效學
  • 預後
  • 代表
  • 驗證
  • 功效
  • 預測性
  • 其他

第 10 章全球癌症生物標誌物市場：按服務分類

  • 檢測開發
  • 樣品製備
  • 測試
  • 生物標誌物
  • 其他

第 11 章全球癌症生物標誌物市場：按地區

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 意大利
    • 法國
    • 西班牙
    • 其他歐洲
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳大利亞
    • 新西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 其他南美洲
  • 中東和非洲
    • 沙特阿拉伯
    • 阿拉伯聯合酋長國
    • 卡塔爾
    • 南非
    • 其他中東和非洲地區

第12章主要發展

  • 合同、夥伴關係、協作和合資企業
  • 收購與合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第13章公司簡介

  • Abbott Laboratories
  • Myriad Genetics, Inc.
  • F. Hoffmann-LA Roche Ltd.
  • Asuragen, Inc.
  • Biomerieux SA
  • Seegene Technologies, INC.
  • Thermo Fisher Scientific INC.
  • R&d Systems, Inc.
  • Becton Dickinson and Company
  • Qiagen N.V.
  • Hologic, Inc.
  • Illumina, Inc.
  • Bio-Rad Laboratories, INC.
  • Agilent Technologies
  • Merck Millipore
Product Code: SMRC23057

According to Stratistics MRC, the Global Cancer Biomarkers Market is accounted for $14.70 billion in 2022 and is expected to reach $40.92 billion by 2028 growing at a CAGR of 18.6% during the forecast period. In oncology, biomarkers are substances that a tumour or a particular human body reaction secretes to indicate the presence of malignancy. Using diverse genomes and proteomics methods, biomarkers enable early cancer detection and quick, noninvasive diagnosis of the disease. Applications for biomarkers include prognostics, personalised medicine, drug research and development, and cancer diagnosis.

According to, the National Cancer Institute, in 2018, an estimated 1,735,350 new cases of cancer was diagnosed in the United States. According to the World Cancer Research Fund International, an estimated 18.0 million people were suffering from globally in 2018. Lung and breast cancers were the most common cancers reported globally, contributing to 12.3% of the total number of the cases diagnosed in 2018.

Market Dynamics:

Driver:

Rising prevalence of cancer

Cancer biomarkers are widely utilised in personalised medicine, companion diagnostics, and other disease diagnostics, including risk assessment for disease and drug development. One of the primary factors anticipated to propel the growth of the cancer biomarkers market during the forecast period is the increasing utilisation of biomarkers in disease diagnosis. Globally increasing rates of cancer are driving up demand for early disease detection and, in turn, driving the market's expansion. The demand for cancer diagnostics and treatment is expected to raise as the prevalence of cancer biomarkers increases in both emerging and developed nations.

Restraint:

High treatment cost

An international issue that jeopardises patient access to care and the effectiveness of cancer therapy is the rising price of cancer medications. The cost of drugs varies widely between different countries. In nations without universal health coverage, patients must pay for their medical care. Most patients in low- and middle-income countries cannot afford novel cancer therapies. The most serious risks are to younger patients, new immigrants, people of colour, and those without private health insurance. Value-based oncology treatment pricing can promote the creation of better therapeutics and cut down on unnecessary spending.

Opportunity:

Presence of potential pipeline candidates

The pharmaceutical sector has made a large investment in the search for novel biomarkers that can be used to monitor and identify cancer. Several contenders' development cycles are coming to a close. This is expected to significantly increase market growth. For instance, Lund University Hospital is working with the South Sweden Breast Cancer Group to undertake clinical trials comparing the efficiency and safety of atorvastatin. The creation of new biomarkers for the early diagnosis of cancer should be advantageous for the oncology biomarker sector. Due to the growing availability of cancer biomarker-related goods and diagnostics, the market is anticipated to expand.

Threat:

Lack of reimbursement policies for biomarker testing

The lack of reimbursement policies for biomarker testing in emerging and developed nations is one of the factors that is restricting the demand for these biomarkers globally, despite the rising prevalence of cancer around the world and the growing number of patients needing diagnostic tests. The high cost of cancer diagnosis and treatment in developing nations is another significant issue limiting the market's growth. Due to this, fewer patients are having biomarker testing, and more patients are favouring other inexpensive detection methods.

COVID-19 Impact:

The COVID-19 pandemic had a negative impact on the cancer biomarkers market, owing to the interrupted research and development activities during this period. Additionally, the SARS-CoV-2 infection can produce biomarker data that are difficult to interpret. For instance, according to information supplied by the Society for Endocrinology in September 2020, indicators of the immunological response to cancer may be difficult to interpret due to the potential confounding effect of the strong immune response to acute viral infection. In addition, the U.K. delayed normal cancer screening as a result of the COVID-19 pandemic, according to a National Centre for Biotechnology Information report.

The breast cancer segment is expected to be the largest during the forecast period

The breast cancer segment is estimated to have a lucrative growth. A huge patient pool undergoing diagnostic testing is a result of the rising incidence of breast cancer and increased awareness of the diagnosis of the disease. Some of the key reasons influencing the growth of the breast cancer segment include this along with an increase in research activities concentrating on new biomarkers for breast cancer detection.

The diagnostics segment is expected to have the highest CAGR during the forecast period

The diagnostics segment is anticipated to witness the fastest CAGR growth during the forecast period, due to advancements in cancer detection and therapy, the emphasis has switched from immediate objectives like curing the disease to longer-term objectives like improving the quality of life for cancer survivors, particularly those with paediatric tumours. It is anticipated that the growing acceptance of companion diagnostic tests for cancer treatments will bolster market growth.

Region with highest share:

Asia Pacific is projected to hold the largest market share during the forecast period owing to the high number of cancer cases in the region. Rising public awareness of the need of early cancer detection is one of the primary factors propelling the market's revenue growth in this area. Additionally, a significant population base in the area contributes to the market's revenue growth.

Region with highest CAGR:

Europe is projected to have the highest CAGR over the forecast period. There has been the identification of a critical biomarker for estimating cancer risk and early cancer detection. A quantitative method to determine when someone is likely to develop cancer is provided by biomarkers, especially those linked to hereditary factors. The growing demand for cancer diagnostics, which is powered by the rising incidence rates of different malignancies, is what is driving market expansion in this region.

Key players in the market:

Some of the key players profiled in the Cancer Biomarkers Market include Abbott Laboratories, Myriad Genetics, Inc., F. Hoffmann-LA Roche Ltd., Asuragen, Inc., Biomerieux SA, Seegene Technologies, INC., Thermo Fisher Scientific INC., R&d Systems, Inc., Becton Dickinson and Company, Qiagen N.V., Hologic, Inc., Illumina, Inc., Bio-Rad Laboratories, INC., Agilent Technologies and Merck Millipore.

Key Developments:

In March 2021, Roche made an announcement that company has received the approval from US Food and Drug Administration for VENTANA ALK (D5F3) CDx Assay as a companion diagnostic. This assay test is the only test which was approved by FDA for as a companion diagnostic for LORBRENA and will help in identifying patients with this cancer biomarker quickly so they can be given more effective treatment.

In November 2020, Agilent Technologies Inc. made an announcement of the launch of the Biomarker Pathologist Training Program which is a worldwide initiative built to enable pathologists to score biomarkers precisely. The program initially was available in Europe and North America, along with China and Asia which utilizes a digital platform.

In July 2020, Thermo Fisher Scientific has announced that the company has signed a companion diagnostic (CDx) agreement with Chugai Pharmaceutical Co., Ltd., and has applied to the Ministry of Health, Labour and Welfare (MHLW) to increase the use of the Oncomine Dx Target Test in Japan. This agreement focuses on accelerating the local biomarker testing of NSCLC patients eligible for entrectinib in Japan.

Cancer Types Covered:

  • Melanoma
  • Bladder Cancer
  • Breast Cancer
  • Kidney Cancer
  • Prostate Cancer
  • Lung Cancer
  • Non-Hodgkin's Lymphoma
  • Colorectal Cancer
  • Thyroid Cancer
  • Leukemia
  • Other Cancer Types

Products Covered:

  • Software
  • Consumables
  • Growth Hormone Therapy
  • Services
  • Other Products

Profiling Technologies Covered:

  • Immunoassay
  • Omics Technologies
  • Cytogenetics
  • Imaging Technologies
  • Bioinformatics
  • Other Profiling Technologies

Applications Covered:

  • Prognostics
  • Diagnostics
  • Risk Assessment
  • Research & Development
  • Hospitals & Specialty Clinics
  • Pharmaceutical & Biotechnology Companies
  • Other Applications

Biomarkers Types Covered:

  • Genetic Biomarkers
  • Protein Biomarkers
  • Safety
  • Pharmacodynamics
  • Prognostic
  • Surrogate
  • Validation
  • Efficacy
  • Predictive
  • Other Biomarker Types

Services Covered:

  • Assay Development
  • Sample Preparation
  • Testing
  • Biomarkers
  • Other Services

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2020, 2021, 2022, 2025, and 2028
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 Technology Analysis
  • 3.8 Application Analysis
  • 3.9 Emerging Markets
  • 3.10 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Cancer Biomarkers Market, By Cancer Type

  • 5.1 Introduction
  • 5.2 Melanoma
  • 5.3 Bladder Cancer
  • 5.4 Breast Cancer
  • 5.5 Kidney Cancer
  • 5.6 Prostate Cancer
  • 5.7 Lung Cancer
  • 5.8 Non-Hodgkin's Lymphoma
  • 5.9 Colorectal Cancer
  • 5.10 Thyroid Cancer
  • 5.11 Leukemia
  • 5.12 Other Cancer Types

6 Global Cancer Biomarkers Market, By Product

  • 6.1 Introduction
  • 6.2 Software
  • 6.3 Consumables
  • 6.4 Growth Hormone Therapy
  • 6.5 Services
  • 6.6 Other Products

7 Global Cancer Biomarkers Market, By Profiling Technologies

  • 7.1 Introduction
  • 7.2 Immunoassay
  • 7.3 Omics Technologies
  • 7.4 Cytogenetics
  • 7.5 Imaging Technologies
  • 7.6 Bioinformatics
  • 7.7 Other Profiling Technologies

8 Global Cancer Biomarkers Market, By Application

  • 8.1 Introduction
  • 8.2 Prognostics
  • 8.3 Diagnostics
  • 8.4 Risk Assessment
  • 8.5 Research & Development
  • 8.6 Hospitals & Specialty Clinics
  • 8.7 Pharmaceutical & Biotechnology Companies
  • 8.8 Other Applications

9 Global Cancer Biomarkers Market, By Biomarkers Type

  • 9.1 Introduction
  • 9.2 Genetic Biomarkers
  • 9.3 Protein Biomarkers
  • 9.4 Safety
  • 9.5 Pharmacodynamics
  • 9.6 Prognostic
  • 9.7 Surrogate
  • 9.8 Validation
  • 9.9 Efficacy
  • 9.10 Predictive
  • 9.11 Other Biomarker Types

10 Global Cancer Biomarkers Market, By Service

  • 10.1 Introduction
  • 10.2 Assay Development
  • 10.3 Sample Preparation
  • 10.4 Testing
  • 10.5 Biomarkers
  • 10.6 Other Services

11 Global Cancer Biomarkers Market, By Geography

  • 11.1 Introduction
  • 11.2 North America
    • 11.2.1 US
    • 11.2.2 Canada
    • 11.2.3 Mexico
  • 11.3 Europe
    • 11.3.1 Germany
    • 11.3.2 UK
    • 11.3.3 Italy
    • 11.3.4 France
    • 11.3.5 Spain
    • 11.3.6 Rest of Europe
  • 11.4 Asia Pacific
    • 11.4.1 Japan
    • 11.4.2 China
    • 11.4.3 India
    • 11.4.4 Australia
    • 11.4.5 New Zealand
    • 11.4.6 South Korea
    • 11.4.7 Rest of Asia Pacific
  • 11.5 South America
    • 11.5.1 Argentina
    • 11.5.2 Brazil
    • 11.5.3 Chile
    • 11.5.4 Rest of South America
  • 11.6 Middle East & Africa
    • 11.6.1 Saudi Arabia
    • 11.6.2 UAE
    • 11.6.3 Qatar
    • 11.6.4 South Africa
    • 11.6.5 Rest of Middle East & Africa

12 Key Developments

  • 12.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 12.2 Acquisitions & Mergers
  • 12.3 New Product Launch
  • 12.4 Expansions
  • 12.5 Other Key Strategies

13 Company Profiling

  • 13.1 Abbott Laboratories
  • 13.2 Myriad Genetics, Inc.
  • 13.3 F. Hoffmann-LA Roche Ltd.
  • 13.4 Asuragen, Inc.
  • 13.5 Biomerieux SA
  • 13.6 Seegene Technologies, INC.
  • 13.7 Thermo Fisher Scientific INC.
  • 13.8 R&d Systems, Inc.
  • 13.9 Becton Dickinson and Company
  • 13.10 Qiagen N.V.
  • 13.11 Hologic, Inc.
  • 13.12 Illumina, Inc.
  • 13.13 Bio-Rad Laboratories, INC.
  • 13.14 Agilent Technologies
  • 13.15 Merck Millipore

List of Tables

  • Table 1 Global Cancer Biomarkers Market Outlook, By Region (2020-2028) ($MN)
  • Table 2 Global Cancer Biomarkers Market Outlook, By Cancer Type (2020-2028) ($MN)
  • Table 3 Global Cancer Biomarkers Market Outlook, By Melanoma (2020-2028) ($MN)
  • Table 4 Global Cancer Biomarkers Market Outlook, By Bladder Cancer (2020-2028) ($MN)
  • Table 5 Global Cancer Biomarkers Market Outlook, By Breast Cancer (2020-2028) ($MN)
  • Table 6 Global Cancer Biomarkers Market Outlook, By Kidney Cancer (2020-2028) ($MN)
  • Table 7 Global Cancer Biomarkers Market Outlook, By Prostate Cancer (2020-2028) ($MN)
  • Table 8 Global Cancer Biomarkers Market Outlook, By Lung Cancer (2020-2028) ($MN)
  • Table 9 Global Cancer Biomarkers Market Outlook, By Non-Hodgkin's Lymphoma (2020-2028) ($MN)
  • Table 10 Global Cancer Biomarkers Market Outlook, By Colorectal Cancer (2020-2028) ($MN)
  • Table 11 Global Cancer Biomarkers Market Outlook, By Thyroid Cancer (2020-2028) ($MN)
  • Table 12 Global Cancer Biomarkers Market Outlook, By Leukemia (2020-2028) ($MN)
  • Table 13 Global Cancer Biomarkers Market Outlook, By Other Cancer Types (2020-2028) ($MN)
  • Table 14 Global Cancer Biomarkers Market Outlook, By Product (2020-2028) ($MN)
  • Table 15 Global Cancer Biomarkers Market Outlook, By Software (2020-2028) ($MN)
  • Table 16 Global Cancer Biomarkers Market Outlook, By Consumables (2020-2028) ($MN)
  • Table 17 Global Cancer Biomarkers Market Outlook, By Growth Hormone Therapy (2020-2028) ($MN)
  • Table 18 Global Cancer Biomarkers Market Outlook, By Services (2020-2028) ($MN)
  • Table 19 Global Cancer Biomarkers Market Outlook, By Other Products (2020-2028) ($MN)
  • Table 20 Global Cancer Biomarkers Market Outlook, By Profiling Technologies (2020-2028) ($MN)
  • Table 21 Global Cancer Biomarkers Market Outlook, By Immunoassay (2020-2028) ($MN)
  • Table 22 Global Cancer Biomarkers Market Outlook, By Omics Technologies (2020-2028) ($MN)
  • Table 23 Global Cancer Biomarkers Market Outlook, By Cytogenetics (2020-2028) ($MN)
  • Table 24 Global Cancer Biomarkers Market Outlook, By Imaging Technologies (2020-2028) ($MN)
  • Table 25 Global Cancer Biomarkers Market Outlook, By Bioinformatics (2020-2028) ($MN)
  • Table 26 Global Cancer Biomarkers Market Outlook, By Other Profiling Technologies (2020-2028) ($MN)
  • Table 27 Global Cancer Biomarkers Market Outlook, By Application (2020-2028) ($MN)
  • Table 28 Global Cancer Biomarkers Market Outlook, By Prognostics (2020-2028) ($MN)
  • Table 29 Global Cancer Biomarkers Market Outlook, By Diagnostics (2020-2028) ($MN)
  • Table 30 Global Cancer Biomarkers Market Outlook, By Risk Assessment (2020-2028) ($MN)
  • Table 31 Global Cancer Biomarkers Market Outlook, By Research & Development (2020-2028) ($MN)
  • Table 32 Global Cancer Biomarkers Market Outlook, By Hospitals & Specialty Clinics (2020-2028) ($MN)
  • Table 33 Global Cancer Biomarkers Market Outlook, By Pharmaceutical & Biotechnology Companies (2020-2028) ($MN)
  • Table 34 Global Cancer Biomarkers Market Outlook, By Other Applications (2020-2028) ($MN)
  • Table 35 Global Cancer Biomarkers Market Outlook, By Biomarkers Type (2020-2028) ($MN)
  • Table 36 Global Cancer Biomarkers Market Outlook, By Genetic Biomarkers (2020-2028) ($MN)
  • Table 37 Global Cancer Biomarkers Market Outlook, By Protein Biomarkers (2020-2028) ($MN)
  • Table 38 Global Cancer Biomarkers Market Outlook, By Safety (2020-2028) ($MN)
  • Table 39 Global Cancer Biomarkers Market Outlook, By Pharmacodynamics (2020-2028) ($MN)
  • Table 40 Global Cancer Biomarkers Market Outlook, By Prognostic (2020-2028) ($MN)
  • Table 41 Global Cancer Biomarkers Market Outlook, By Surrogate (2020-2028) ($MN)
  • Table 42 Global Cancer Biomarkers Market Outlook, By Validation (2020-2028) ($MN)
  • Table 43 Global Cancer Biomarkers Market Outlook, By Efficacy (2020-2028) ($MN)
  • Table 44 Global Cancer Biomarkers Market Outlook, By Predictive (2020-2028) ($MN)
  • Table 45 Global Cancer Biomarkers Market Outlook, By Other Biomarker Types (2020-2028) ($MN)
  • Table 46 Global Cancer Biomarkers Market Outlook, By Service (2020-2028) ($MN)
  • Table 47 Global Cancer Biomarkers Market Outlook, By Assay Development (2020-2028) ($MN)
  • Table 48 Global Cancer Biomarkers Market Outlook, By Sample Preparation (2020-2028) ($MN)
  • Table 49 Global Cancer Biomarkers Market Outlook, By Testing (2020-2028) ($MN)
  • Table 50 Global Cancer Biomarkers Market Outlook, By Biomarkers (2020-2028) ($MN)
  • Table 51 Global Cancer Biomarkers Market Outlook, By Other Services (2020-2028) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.